As reviewed recently in a large, retrospective cohort (11) and prior metaanalyses (6,12), a substantial body of evidence exists to support the use of 68Ga-PSMA-11 in BCR of prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.